Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.480.02%
QQQ
714.89-
BTC/USD
77195.040.1037%
DIA
525.910.02%
GLD
398.290.12%
TLT
80.930.07%

Amneal Pharmaceuticals Inc

AMRXNASDAQ
Trade with Public
Trade with Public
$17.01
0.140.83%
At close: Sep 11, 5:00 PM EST
$17.01
N/A
After Hours: Sep 11, 4:18 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Amneal Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Amneal Pharmaceuticals (AMRX).

Price Target Range — 11 Quarters

Analyst Consensus — 7 Analysts

7Buy
Consensus RatingBuy# Analysts7Avg. Consensus PT$16Upside to Avg. PT-7.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 9, 2026Leerink PartnersDaniel ClarkInitiateOutperform$23
Aug 26, 2026JP MorganChris SchottReinstatesOverweight$22
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $23

Leerink Partners analyst Daniel Clark initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $23.
Benzinga Newsdesk

PRO
JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target

JP Morgan analyst Chris Schott reinstates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and announces $22 price target.
Benzinga Newsdesk

PRO
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25

UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $23 to $25.
Benzinga Newsdesk

PRO
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $23

UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $19 to $23.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $16

Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $15 to $16.
Benzinga Newsdesk

PRO
UBS Initiates Coverage On Amneal Pharmaceuticals with Buy Rating, Announces Price Target of $19

UBS analyst Ashwani Verma initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy rating and announces Price Target of $19.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved